ISU Abxis KRX:086890KOSDAQ
이수앱지스 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked10since Sep 11
In Q2 2026, ISU Abxis reported revenue of ₩14.9bn, down 34.6% year on year, and operating profit of ₩479m. ISU Abxis (이수앱지스) appeared in 0 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Sep 21 with 7 articles. The most common catalyst was clinical & approvals (1). It was most often mentioned alongside Vaxcell-Bio Therapeutics and Inventera.
ISU Abxis quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩14.9bn | -34.6% | ₩479m margin 3.2% | ₩3.2bn |
| Q1 2026 | ₩9.5bn | +31.6% | −₩3.4bn margin −36.4% | −₩202m |
| Q4 2025 derived | ₩10.9bn | -47.1% | −₩7.8bn margin −71.8% | −₩10.9bn |
| Q3 2025 | ₩15.7bn | +79.5% | ₩562m margin 3.6% | −₩255m |
| Q2 2025 | ₩22.8bn | +59.2% | ₩9.4bn margin 41.1% | ₩9.2bn |
| Q1 2025 | ₩7.2bn | -56.5% | −₩463m margin −6.5% | −₩8.8bn |
| Q4 2024 derived | ₩20.6bn | +24.7% | ₩5.3bn margin 25.4% | ₩27.9bn |
| Q3 2024 | ₩8.8bn | -40.1% | ₩145m margin 1.7% | ₩1.1bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
ISU Abxis top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4
- 5
- 6
Latest ISU Abxis news Korean headlines
-
이수앱지스, 파바갈 페루 첫 수출…희귀질환 해외공략 확대
2 more on this story · 2 outlets
- 이수앱지스 ‘파바갈’ 페루 첫 수출…희귀질환 치료제 해외 공급 넓힌다메디컬투데이 · Sep 21 16:02
- 이수앱지스 ‘파바갈’ 페루 첫 수출…희귀질환 치료제 해외 공급 넓힌다알파경제 · Sep 21 16:02
-
이수앱지스, ‘파바갈·애브서틴’ 해외시장 확대...중남미·중동·아프리카 공략
1 more on this story · 1 outlets
- 이수앱지스, '파바갈·애브서틴' 앞세워 해외시장 공략 확대프라임경제 · Sep 21 09:35